HORMONE RECEPTOR POSITIVE BREAST CANCER

This adverse event was reported 71 times

These drugs are most commonly taken by patients reporting HORMONE RECEPTOR POSITIVE BREAST CANCER:

# Drug Count
0 LETROZOLE 20
1 LETROZOLE TABLETS 19
2 PACLITAXEL 18
3 EXEMESTANE 17
4 CAPECITABINE 14
5 EVEROLIMUS 14
6 GEMCITABINE HYDROCHLORIDE 14
7 CARBOPLATIN 13
8 EVEROLIMUS TABLETS 13
9 FULVESTRANT 12
See all common drugs associated with HORMONE RECEPTOR POSITIVE BREAST CANCER

HORMONE RECEPTOR POSITIVE BREAST CANCER is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 DOXORUBICIN HYDROCHLORIDE LIPOSOME 1 0.0115
1 TAMOXIFEN CITRATE 10 0.0021
2 EVEROLIMUS TABLETS 13 0.0015
3 VINORELBINE 7 0.0014
4 EPIRUBICIN HYDROCHLORIDE 4 0.0014
5 COLLAGENASE SANTYL 1 0.0012
6 EXEMESTANE 17 0.0011
7 LETROZOLE TABLETS 19 0.0008
8 ERIBULIN MESYLATE 2 0.0008
9 FULVESTRANT 12 0.0007
See all drugs enriched for association with HORMONE RECEPTOR POSITIVE BREAST CANCER

HORMONE RECEPTOR POSITIVE BREAST CANCER is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Estrogen Receptor Antagonist [EPC] 12 0.0007
1 Aromatase Inhibitor [EPC] 30 0.0004
2 Janus Kinase Inhibitor [EPC] 1 0.0003
3 Microtubule Inhibitor [EPC] 19 0.0002
4 HER2/neu Receptor Antagonist [EPC] 8 0.0002
5 Platinum-based Drug [EPC] 14 0.0001
6 Nucleoside Metabolic Inhibitor [EPC] 14 0.0001
7 Progesterone [EPC] 1 0.0001
8 Kinase Inhibitor [EPC] 21 0.0001
9 Rifamycin Antibacterial [EPC] 1 0.0001
See all drug classes enriched for association with HORMONE RECEPTOR POSITIVE BREAST CANCER